Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

Huygens, Simone; Versteegh, Matthijs

doi:10.1016/j.jval.2021.05.020

Cited by 14 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this research, we modeled how with the insights from digital biomarker interventions like MS sherpa (efficacy), neurologists together with pwMS have the potential to decide earlier to switch to more effective MS medication, with the intention to prevent or slow down disability worsening and disease progression. The recent Huygens and Versteegh MS model [25] that simulates the disease progress over the lifetime of a patient was used to show whether using MS sherpa to support treatment decisions would be cost-effective. The eHTA showed that under all efficacy assumptions MS sherpa is cost-effective from both a societal and health care perspective in the MS care path.…”

Section: Principal Results and Implications For Clinical Practice And Ms Societymentioning

confidence: 99%

“…In the Netherlands, the National Health Care Institute determines the reference value for cost-effectiveness, based on the disease burden of the health care problem under study [24]. For MS, this value is set at EUR 50,000 per QALY [25].…”

Section: (Early) Health Technology Assessment ((E)hta)mentioning

confidence: 99%

“…In this article, we describe an eHTA analysis for the potential impact of MS sherpa, both from the societal and health care perspective using a recently published decision analytic model for MS treatments [25]. The analysis focused on the impact of MS sherpa on treatment decisions, and more specifically on switches of MS medication based on disease insights achieved with MS sherpa.…”

Section: (Early) Health Technology Assessment ((E)hta)mentioning

confidence: 99%

“…The impact of digital biomarkers on treatment decisions is one of the important concepts to be tested for the MS field. This ICER is compared to the reference value for the maximum costs that the society is willing to pay for 1 additional QALY within MS in the Netherlands [25].…”

Section: (Early) Health Technology Assessment ((E)hta)mentioning

confidence: 99%

“…The CEA was performed using the MS model developed by Huygens and Versteegh [25]. This model describes the lifetime of a pwMS based on MS relapses (Annual Relapse Rate (ARR)) and MS disease progression (EDSS).…”

Section: Ms Model and Clinical Costs And Quality Of Life Inputmentioning

confidence: 99%

See 4 more Smart Citations

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

Cloosterman¹,

Wijnands²,

Huygens³

et al. 2021

Brain Sciences

Self Cite

View full text Add to dashboard Cite

(1) Background: Monitoring of Multiple Sclerosis (MS) with eHealth interventions or digital biomarkers provides added value to the current care path. Evidence in the literature is currently scarce. MS sherpa is an eHealth intervention with digital biomarkers, aimed at monitoring symptom progression and disease activity. To show the added value of digital biomarker–based eHealth interventions to the MS care path, an early Health Technology Assessment (eHTA) was performed, with MS sherpa as an example, to assess the potential impact on treatment switches. (2) Methods: The eHTA was performed according to the Dutch guidelines for health economic evaluations. A decision analytic MS model was used to estimate the costs and benefits of MS standard care with and without use of MS sherpa, expressed in incremental cost-effectiveness ratios (ICERs) from both societal and health care perspectives. The efficacy of MS sherpa on early detection of active disease and the initiation of a treatment switch were modeled for a range of assumed efficacy (5%, 10%, 15%, 20%). (3) Results: From a societal perspective, for the efficacy of 15% or 20%, MS sherpa became dominant, which means cost-saving compared to the standard of care. MS sherpa is cost-effective in the 5% and 10% scenarios (ICERs EUR 14,535 and EUR 4069, respectively). From the health care perspective, all scenarios were cost-effective. Sensitivity analysis showed that increasing the efficacy of MS sherpa in detecting active disease early leading to treatment switches be the most impactful factor in the MS model. (4) Conclusions: The results indicate the potential of eHealth interventions to be cost-effective or even cost-saving in the MS care path. As such, digital biomarker–based eHealth interventions, like MS sherpa, are promising cost-effective solutions in optimizing MS disease management for people with MS, by detecting active disease early and helping neurologists in decisions on treatment switch.

show abstract

Section: Principal Results and Implications For Clinical Practice And Ms Societymentioning

confidence: 99%

Section: (Early) Health Technology Assessment ((E)hta)mentioning

confidence: 99%

Section: (Early) Health Technology Assessment ((E)hta)mentioning

confidence: 99%

Section: (Early) Health Technology Assessment ((E)hta)mentioning

confidence: 99%

Section: Ms Model and Clinical Costs And Quality Of Life Inputmentioning

confidence: 99%

See 3 more Smart Citations

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

Cloosterman¹,

Wijnands²,

Huygens³

et al. 2021

Brain Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations

Wang,

Pouwels,

Ramaekers

et al. 2024

PharmacoEconomics

View full text Add to dashboard Cite

Background The current use of health economic decision models in HTA is mostly confined to single use cases, which may be inefficient and result in little consistency over different treatment comparisons, and consequently inconsistent health policy decisions, for the same disorder. Multi-use disease models (MUDMs) (other terms: generic models, whole disease models, disease models) may offer a solution. However, much is uncertain about their definition and application. The current research aimed to develop a blueprint for the application of MUDMs. Methods We elicited expert opinion using a two-round modified Delphi process. The panel consisted of experts and stakeholders in health economic modelling from various professional backgrounds. The first questionnaire concerned definition, terminology, potential applications, issues and recommendations for MUDMs and was based on an exploratory scoping review. In the second round, the panel members were asked to reconsider their input, based on feedback regarding first-round results, and to score issues and recommendations for priority. Finally, adding input from external advisors and policy makers in a structured way, an overview of issues and challenges was developed during two team consensus meetings. Results In total, 54 respondents contributed to the panel results. The term ‘multi-use disease models’ was proposed and agreed upon, and a definition was provided. The panel prioritized 10 potential applications (with comparing alternative policies and supporting resource allocation decisions as the top 2), while 20 issues (with model transparency and stakeholders’ roles as the top 2) were identified as challenges. Opinions on potential features concerning operationalization of multi-use models were given, with 11 of these subsequently receiving high priority scores ( regular updates and revalidation after updates were the top 2). Conclusions MUDMs would improve on current decision support regarding cost-effectiveness information. Given feasibility challenges, this would be most relevant for diseases with multiple treatments, large burden of disease and requiring more complex models. The current overview offers policy makers a starting point to organize the development, use, and maintenance of MUDMs and to support choices concerning which diseases and policy decisions they will be helpful for. Supplementary Information The online version contains supplementary material available at 10.1007/s40273-024-01376-w.

show abstract

Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifying therapies: Achievements and opportunities

Smolders,

Hamann,

Huitinga

2024

Handbook of Clinical Neurology

View full text Add to dashboard Cite

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

Cited by 14 publications

References 32 publications

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations

Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifying therapies: Achievements and opportunities

Contact Info

Product

Resources

About